Table 1.

Baseline parameters and distribution of TSR in clinico-pathological subgroups

Characteristics	Number of patients	Stroma-low		Stroma-high		χ2 value	P value
		N	%	N	%
Age
≤ 50	149	97	63.4%	52	59.8%	0.310	0.578
> 50	91	56	36.6%	35	40.2%
Histopathological Grade
I	40	27	17.6%	13	14.9%	1.338	0.512
II	141	92	60.1%	49	56.3%
III	59	34	22.2%	25	28.7%
Molecular subtypes
TNBC	63	37	24.2%	26	29.9%	4.799	0.091
HER-2 positive	61	34	22.2%	27	31.0%
Luminal-HER2-negative	116	82	53.6%	34	39.1%
Nodal status
Positive	131	77	50.3%	54	62.1%	3.085	0.079
Negative	109	76	49.7%	33	37.9%
ER status
Positive	106	78	51.0%	28	32.2%	7.946	0.005
Negative	134	75	49.0%	59	67.8%
HER-2 status
Positive	61	34	22.2%	27	31.0%	2.272	0.132
Negative	179	119	77.8%	60	69.0%
PR status
Positive	107	76	49.7%	31	35.6%	4.426	0.035
Negative	133	77	50.3%	56	64.4%
Menopausal status
Premenopausal	134	92	60.1%	42	48.3%	3.161	0.075
Postmenopausal	106	61	39.9%	45	51.7%
Tumor size (in cm)
T1 (T ≤ 2)	35	21	13.7%	14	16.1%	5.945	0.051
T2 (2 < T ≤ 5)	162	111	72.5%	51	58.6%
T3 (T > 5)	43	21	13.7%	22	25.3%